×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
UTHR – united therapeutics corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
UTHR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/30
02:40 am
uthr
Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March? [Yahoo! Finance]
Low
Report
Is United Therapeutics (UTHR) The Most Expensive Stock Insiders Are Dumping In March? [Yahoo! Finance]
3/18
09:50 am
uthr
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off [Yahoo! Finance]
Low
Report
2 Healthcare Stocks with Solid Fundamentals and 1 to Brush Off [Yahoo! Finance]
3/17
09:09 am
uthr
Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System [Yahoo! Finance]
Medium
Report
Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System [Yahoo! Finance]
3/10
05:10 am
uthr
For Patients Needing Transplants, Hope Arrives on Tiny Hooves [The New York Times]
Low
Report
For Patients Needing Transplants, Hope Arrives on Tiny Hooves [The New York Times]
3/4
07:00 am
uthr
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
Low
Report
United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
2/28
11:42 am
uthr
United Therapeutics price target lowered to $420 from $430 at Leerink [Yahoo! Finance]
Low
Report
United Therapeutics price target lowered to $420 from $430 at Leerink [Yahoo! Finance]
2/27
10:03 pm
uthr
United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Low
Report
United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
2/27
09:22 am
uthr
United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $425.00 price target on the stock.
Medium
Report
United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $425.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
2/26/2025
06:30 am
uthr
united therapeutics corporation
BEAT
Report
-12.8%
united therapeutics corporation
2/26/2025
06:30 am
uthr
united therapeutics corporation
BEAT
Report
-10.2%
united therapeutics corporation
2/26/2025
06:30 am
uthr
united therapeutics corporation
BEAT
Report
-10.2%
united therapeutics corporation
2/26/2025
06:30 am
uthr
united therapeutics corporation
BEAT
Report
-11.4%
united therapeutics corporation
Date
Time
Symbol
Headline
Impact
3/25
04:31 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Mar 24 Filed by: Thompson Tommy G
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Mar 24 Filed by: Thompson Tommy G
3/24
04:48 pm
uthr
Form 144 UNITED THERAPEUTICS Corp Filed by: Thompson Tommy G
Low
Report
Form 144 UNITED THERAPEUTICS Corp Filed by: Thompson Tommy G
3/20
06:11 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Mar 19 Filed by: PATUSKY CHRISTOPHER
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Mar 19 Filed by: PATUSKY CHRISTOPHER
3/19
04:11 pm
uthr
Form 144 UNITED THERAPEUTICS Corp Filed by: PATUSKY CHRISTOPHER
Low
Report
Form 144 UNITED THERAPEUTICS Corp Filed by: PATUSKY CHRISTOPHER
3/11
04:31 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Mar 07 Filed by: ROTHBLATT MARTINE A
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Mar 07 Filed by: ROTHBLATT MARTINE A
3/11
04:30 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Mar 10 Filed by: BENKOWITZ MICHAEL
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Mar 10 Filed by: BENKOWITZ MICHAEL
3/10
04:24 pm
uthr
Form 144 UNITED THERAPEUTICS Corp Filed by: BENKOWITZ MICHAEL
Medium
Report
Form 144 UNITED THERAPEUTICS Corp Filed by: BENKOWITZ MICHAEL
3/7
04:33 pm
uthr
Form 4 UNITED THERAPEUTICS Corp For: Mar 06 Filed by: MAHON PAUL A
Low
Report
Form 4 UNITED THERAPEUTICS Corp For: Mar 06 Filed by: MAHON PAUL A
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/10
Jefferines likes United Therapeutics in premarket analyst action [Seeking Alpha]
8.4%
2/24 United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints 7.8%
3/27 Form 4 UNITED THERAPEUTICS Corp For: Mar 25 Filed by: SULLIVAN LOUIS W 5.9%
3/18 Form 4 UNITED THERAPEUTICS Corp For: Mar 17 Filed by: PATUSKY CHRISTOPHER 5.3%
6/28 Form 4 UNITED THERAPEUTICS Corp For: Jun 26 Filed by: Mesa Nilda 5.1%
2/4 United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen 5.0%
8/1 United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript [The Motley Fool] 4.8%
3/24 Form 4 UNITED THERAPEUTICS Corp For: Mar 23 Filed by: SULLIVAN LOUIS W 4.3%
4/21 Form 4 UNITED THERAPEUTICS Corp For: Apr 20 Filed by: Giltner Richard 3.9%
1/28 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $237.00 price target on the stock. 3.5%
2/24 United Therapeutics Announces INCREASE Study Of Tyvaso® Meets Primary And All Secondary Endpoints 7.8%
3/27 Form 4 UNITED THERAPEUTICS Corp For: Mar 25 Filed by: SULLIVAN LOUIS W 5.9%
3/18 Form 4 UNITED THERAPEUTICS Corp For: Mar 17 Filed by: PATUSKY CHRISTOPHER 5.3%
6/28 Form 4 UNITED THERAPEUTICS Corp For: Jun 26 Filed by: Mesa Nilda 5.1%
2/4 United Therapeutics Defeats Preliminary Injunction Motion In Litigation With Sandoz And RareGen 5.0%
8/1 United Therapeutics Corporation (UTHR) 2019 Q2 Earnings Call Transcript [The Motley Fool] 4.8%
3/24 Form 4 UNITED THERAPEUTICS Corp For: Mar 23 Filed by: SULLIVAN LOUIS W 4.3%
4/21 Form 4 UNITED THERAPEUTICS Corp For: Apr 20 Filed by: Giltner Richard 3.9%
1/28 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $237.00 price target on the stock. 3.5%
TOP News Decliners
2/26
Q4/2019 12/31/2019 EPS 1.960 ZacksConsensus 2.470 ActVsEst (0.510) - Miss
-6.2%
2/27 United Therapeutics Co. (NASDAQ: UTHR) was upgraded by analysts at Cowen Inc from a "market perform" rating to an "outperform" rating. -4.7%
12/13 Form 8-K UNITED THERAPEUTICS Corp For: Dec 13 -4.1%
6/13 Form 4 UNITED THERAPEUTICS Corp For: Jun 13 Filed by: Giltner Richard -3.5%
6/5 United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference -3.4%
10/30 How United Therapeutics Trounced Wall Street's Q3 Estimates [The Motley Fool] -3.1%
2/25 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $243.00 price target on the stock. -3.0%
12/3 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -2.8%
6/11 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.5%
2/3 United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint -2.2%
2/27 United Therapeutics Co. (NASDAQ: UTHR) was upgraded by analysts at Cowen Inc from a "market perform" rating to an "outperform" rating. -4.7%
12/13 Form 8-K UNITED THERAPEUTICS Corp For: Dec 13 -4.1%
6/13 Form 4 UNITED THERAPEUTICS Corp For: Jun 13 Filed by: Giltner Richard -3.5%
6/5 United Therapeutics Corporation to Present at Goldman Sachs 40th Annual Global Healthcare Conference -3.4%
10/30 How United Therapeutics Trounced Wall Street's Q3 Estimates [The Motley Fool] -3.1%
2/25 United Therapeutics Co. (NASDAQ: UTHR) had its "buy" rating re-affirmed by analysts at Wedbush. They now have a $243.00 price target on the stock. -3.0%
12/3 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -2.8%
6/11 United Therapeutics Co. (NASDAQ: UTHR) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -2.5%
2/3 United Therapeutics Announces Study of Unituxin® (dinutuximab) for Small Cell Lung Cancer Did Not Meet Primary Endpoint -2.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: